Skip to main content
. 2022 May 9;8:61. doi: 10.1038/s41523-022-00423-z

Fig. 4. Cumulative incidence curves for BCFi and OS by ROR score categories for patients with ER-positive/HER2-negative tumors.

Fig. 4

(a, b) all patients (c, d) node-negative, and (e, f) node-positive patients. Overall P-values from log rank test, Gehan’s version for BCFi, for maximum follow-up and for different time intervals. BCFi breast cancer-free interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OS overall survival, ROR risk of recurrence.